blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

Latvia joins the Federated Register
Click here for more information on the Federated Register.

2025-04-16

More...
blank Related links

Extract from the Register of European Patents

EP About this file: EP3922279

EP3922279 - DRUG DELIVERY COMPOSITIONS AND USES THEREOF [Right-click to bookmark this link]
StatusThe patent has been granted
Status updated on  29.11.2024
Database last updated on 26.04.2025
FormerGrant of patent is intended
Status updated on  23.07.2024
FormerExamination is in progress
Status updated on  02.09.2022
FormerRequest for examination was made
Status updated on  17.06.2022
FormerThe application has been published
Status updated on  12.11.2021
Most recent event   Tooltip10.01.2025Correction of patent specificationpublished on 12.02.2025  [2025/07]
Applicant(s)For all designated states
Dana-Farber Cancer Institute, Inc.
450 Brookline Avenue
Boston, MA 02215 / US
[2025/05]
Former [2024/35]For all designated states
Dana Farber Cancer Institute, Inc.
450 Brookline Avenue
Boston, Massachusetts 02215 / US
Former [2021/50]For all designated states
Dana Farber Cancer Institute, Inc.
450 Brookline Avenue
Boston, Massachusetts 02215-5450 / US
Inventor(s)01 / GOLDBERG, Michael Solomon
Brookline, 02446 / US
02 / PARK, Chun Gwon
Boston, 02115 / US
 [2021/50]
Representative(s)Carpmaels & Ransford LLP
One Southampton Row
London WC1B 5HA / GB
[2025/01]
Former [2021/50]HGF
1 City Walk
Leeds LS11 9DX / GB
Application number, filing date21171683.230.08.2017
[2021/50]
Priority number, dateUS201662381456P30.08.2016         Original published format: US 201662381456 P
US201762486814P18.04.2017         Original published format: US 201762486814 P
US201762501464P04.05.2017         Original published format: US 201762501464 P
[2021/50]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP3922279
Date:15.12.2021
Language:EN
[2021/50]
Type: B1 Patent specification 
No.:EP3922279
Date:01.01.2025
Language:EN
[2025/01]
Type: B8 Corrected title page of specification 
No.:EP3922279
Date:12.02.2025
[2025/07]
Search report(s)(Supplementary) European search report - dispatched on:EP06.10.2021
ClassificationIPC:A61L26/00, A61K9/06, A61K47/36, A61K38/17, A61K38/19, A61K39/395
[2021/50]
CPC:
C07K16/2818 (EP,IL,US); A61K39/39541 (EP,IL,US); A61K9/0024 (EP,IL,KR,US);
A61K31/415 (IL,KR); A61K31/444 (EP,IL,US); A61K31/4745 (EP,IL,US);
A61K31/635 (EP,IL,US); A61K35/17 (EP,IL,KR,US); A61K38/1793 (IL,US);
A61K38/19 (EP,IL,KR,US); A61K38/2086 (IL,US); A61K38/21 (IL,KR);
A61K39/395 (IL,KR); A61K39/3955 (IL,US); A61K45/06 (EP,IL,KR,US);
A61K47/36 (EP,IL,KR,US); A61K9/0019 (IL,US); A61K9/06 (EP,IL,KR,US);
A61L26/00 (EP); A61L27/52 (IL,US); A61P35/00 (IL,KR);
A61P35/04 (EP,IL,US); C07H21/04 (EP,IL,US); C07K16/2878 (EP,IL,US);
C07K16/2896 (IL,US); C07K16/30 (IL,US); A61K2039/505 (EP,IL,KR,US);
A61K2300/00 (IL,KR); C07K2317/75 (EP,IL,US) (-)
C-Set:
A61K31/444, A61K2300/00 (EP,US);
A61K31/4745, A61K2300/00 (US,EP);
A61K31/635, A61K2300/00 (US,EP);
A61K38/19, A61K2300/00 (US,EP);
A61K39/39541, A61K2300/00 (EP,US)
(-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2022/29]
Former [2021/50]AL,  AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  RS,  SE,  SI,  SK,  SM,  TR 
TitleGerman:ARZNEIMITTELABGABEZUSAMMENSETZUNGEN UND VERWENDUNGEN DAVON[2021/50]
English:DRUG DELIVERY COMPOSITIONS AND USES THEREOF[2021/50]
French:COMPOSITIONS POUR L'ADMINISTRATION DE MÉDICAMENTS ET LEURS UTILISATIONS[2021/50]
Examination procedure13.06.2022Examination requested  [2022/29]
13.06.2022Date on which the examining division has become responsible
06.09.2022Despatch of a communication from the examining division (Time limit: M06)
15.03.2023Observations by third parties
04.05.2023Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time
14.07.2023Reply to a communication from the examining division
28.07.2023Despatch of a communication from the examining division (Time limit: M06)
07.02.2024Reply to a communication from the examining division
22.03.2024Despatch of a communication from the examining division (Time limit: M04)
04.07.2024Reply to a communication from the examining division
24.07.2024Communication of intention to grant the patent
22.11.2024Fee for grant paid
22.11.2024Fee for publishing/printing paid
22.11.2024Receipt of the translation of the claim(s)
19.12.2024Request for correction of the decision to grant filed
Parent application(s)   TooltipEP17765524.8  / EP3506884
Divisional application(s)EP24223840.0
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the examination report
14.07.2023Request for further processing filed
14.07.2023Full payment received (date of receipt of payment)
Request granted
19.07.2023Decision despatched
Fees paidRenewal fee
12.08.2021Renewal fee patent year 03
12.08.2021Renewal fee patent year 04
12.08.2021Renewal fee patent year 05
29.08.2022Renewal fee patent year 06
28.08.2023Renewal fee patent year 07
27.08.2024Renewal fee patent year 08
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court
See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[A]US2007213393  (HUNTER WILLIAM L [CA], et al);
 [A]US9364545  (JHAN HUA-JING [TW], et al);
 [A]WO2016119308  (UNION HOSPITAL TONGJI MEDICAL COLLEGE HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY [CN]);
 [A]WO2016123573  (HARVARD COLLEGE [US]);
by applicantWO2016057265
 WO2018045058
 US19960620779
 US19850798385
 US19940303216
 US19970957192
 US19980210114
 US19990361544
 US20000528620
 WO2004US32480
 WO2014US38525
 WO2017US13049
 WO2017US13066
otherWO02087563
 US2015094518
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.